Results 91 to 100 of about 3,628 (221)

a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions [PDF]

, 2015
Purpose Response to clopidogrel varies widely with nonresponse rates ranging from 4% to 30%. A reduced function of the gene variant of the CYP2C19 has been associated with lower drug metabolite levels, and hence diminished platelet inhibition.
Ramadan, Wijdan H., Saab, Yolande B., Zeenny, Rony   +2 more
core   +1 more source

Rescue Therapy for Failed Mechanical Thrombectomy in Acute Ischemic Stroke: A Pooled Analysis of the Society of Vascular and Interventional Neurology Registry

Annals of Neurology, Volume 96, Issue 2, Page 343-355, August 2024.
Objective We aimed to evaluate the association between rescue therapy (RT) and functional outcomes compared to medical management (MM) in patients presenting after failed mechanical thrombectomy (MT). Methods This cross‐sectional study utilized prospectively collected and maintained data from the Society of Vascular and Interventional Neurology ...
Aaron Rodriguez‐Calienes, Fazeel M. Siddiqui, Milagros Galecio‐Castillo, Mahmoud H. Mohammaden, Jaydevsinh N. Dolia, Jonathan A. Grossberg, Aqueel Pabaney, Ameer E. Hassan, Wondwossen G. Tekle, Hamzah Saei, Samantha Miller, Shahram Majidi, Johana T. Fifi, Gabrielle Valestin, James E. Siegler, Mary Penckofer, Linda Zhang, Sunil A. Sheth, Sergio Salazar‐Marioni, Ananya Iyyangar, Thanh N. Nguyen, Mohamad Abdalkader, Italo Linfante, Guilherme Dabus, Brijesh P. Mehta, Joy Sessa, Mouhammad A. Jumma, Rebecca M. Sugg, Guillermo Linares, Raul G. Nogueira, David S. Liebeskind, Diogo C. Haussen, Santiago Ortega‐Gutierrez   +32 more
wiley   +1 more source

P2Y12 Receptor Function and Response to Cangrelor in Neonates With Cyanotic Congenital Heart Disease

JACC: Basic to Translational Science, 2017
Shunt thrombosis remains a major cause of morbidity and mortality, especially during the initial palliation for single-ventricle physiology. The authors present evidence that the P2Y12 inhibitor cangrelor may fill a therapeutic void in thromboprophylaxis.
Elisabeth A. Kaza, MD, Matthew C. Egalka, MD, Hairu Zhou, MS, Jianchun Chen, PhD, Denise Evans, MSHS, Jayne Prats, PhD, Ruizhi Li, PhD, Scott L. Diamond, PhD, Julie A. Vincent, MD, Emile A. Bacha, MD, Thomas G. Diacovo, MD   +10 more
doaj   +1 more source

Use of cangrelor in percutaneous coronary interventions: a “new” weapon in the antithrombotic therapeutic armamentarium

REC: Interventional Cardiology (English Ed.), 2020
During the second half of 2019, cangrelor started selling in our country, a “new” antiplatelet drug with especial pharmacological properties that make it especially appealing for the management of certain clinical situations in the percutaneous coronary ...
José Luis Ferreiro, Joan Antoni Gómez-Hospital   +1 more
doaj   +1 more source

The Caspase 1 Inhibitor VX-765 Protects the Isolated Rat Heart via the RISK Pathway [PDF]

, 2018
PURPOSE: Protecting the heart from ischaemia-reperfusion (IR) injury is a major goal in patients presenting with an acute myocardial infarction. Pyroptosis is a novel form of cell death in which caspase 1 is activated and cleaves interleukin 1β.
Arjun, S, Davidson, SM, Do Carmo, H, Petrucci, O, Yellon, DM   +4 more
core   +1 more source

Mechanical thrombectomy using neurovascular catheter from radial artery during acute myocardial infarction: A case report

Clinical Case Reports, Volume 12, Issue 8, August 2024.
Key Clinical Message Coronary occlusion due to large thrombus is frequently encountered during ST‐elevation myocardial infarction (STEMI). Despite guidelines discourage this practice, often thrombus aspiration is necessary to reduce thrombotic burden and to prevent embolization.
Michele Cacia, Cristina Nesta, Vittorio Pascale, Marco Vatrano, Giulia Galiano Leone, Emilia De Luca, Alessandro Ferraro, Vincenzo Antonio Ciconte   +7 more
wiley   +1 more source

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use

Therapeutic Advances in Cardiovascular Disease, 2019
Oral antiplatelet drugs are crucially important for patients with acute coronary syndrome or stable coronary artery disease undergoing percutaneous coronary intervention (PCI).
Davide Capodanno, Rocco P. Milluzzo, Dominick J. Angiolillo   +2 more
doaj   +1 more source

Role of P2RY12 gene variants and biological variation in arterial thrombosis [PDF]

, 2009
Arterial thrombosis is the leading cause of morbidity and mortality in the Western world. Plaque rupture induces arterial thrombus formation, which may result in vascular occlusion.
Rudež, G. (Goran)
core   +1 more source

P2Y12 Receptor Blockade Augments Glycoprotein IIb‐IIIa Antagonist Inhibition of Platelet Activation, Aggregation, and Procoagulant Activity [PDF]

, 2014
Background: New antiplatelet agents that provide greater, more consistent inhibition of the platelet ADP receptor P2Y12 may be used in combination with glycoprotein (GP) IIb‐IIIa antagonists, but their combined effect on platelet function and ...
Barnard, Marc R., Berny‐Lang, Michelle A., Frelinger, Andrew L., Jakubowski, Joseph A., Michelson, Alan D., Sugidachi, Atsuhiro   +5 more
core   +1 more source

Oral P2Y12 inhibitors only versus cangrelor in critically ill patients requiring percutaneous coronary interventions supported by microaxial flow pumps

International Journal of Cardiology: Heart & Vasculature
Background: Oral P2Y12 inhibitors (P2Y12i) may have reduced efficacy in critically ill patients undergoing Impella-supported PCI. The intravenous P2Y12i cangrelor offers rapid and reversible platelet inhibition, but its role in this setting remains ...
Chiara Schaffner, Yanick Spahr, Alessandro Spirito, Gregorio Tersalvi, Irena Majcen, Firat Erdogan, Yuan Zhi, Armin Spahr, Thomas Seiler, Adrian Attinger, Florim Cuculi, Matthias Bossard   +11 more
doaj   +1 more source